66. IgA nephropathy Clinical trials / Disease details


Clinical trials : 275 Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04525729
(ClinicalTrials.gov)
July 1, 202017/8/2020Rituximab and RASi in Patients With IgANA Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA NephropathyIgA NephropathyDrug: Rituximab;Drug: RAS 2410CHENNANDongfang Hospital Affiliated to Tongji University;Shanghai Pudong New Area People's Hospital;Ruijin Hospital North Shanghai Jiao Tong University School of Medicine;Ningbo Municipal Yinzhou District No.2 Hospital;Third Affiliated Hospital, Sun Yat-Sen University;Xiamen Hongai Hospital;Sir Run Run Shaw HospitalRecruiting18 Years75 YearsAll116Phase 4China
2NCT03188887
(ClinicalTrials.gov)
February 20, 20182/5/2017Treatment of IgA Nephropathy According to Renal LesionsTreatment of IgA Nephropathy According to Renal LesionsIgA NephropathyDrug: corticotherapy;Drug: Renin Angiotensin system (RAS) blockade or Inhibitors of sodium glucose transporter 2 (SGLT2i)Assistance Publique - Hôpitaux de ParisNULLActive, not recruiting18 YearsN/AAll62Phase 3France
3ChiCTR-TRC-09000338
2009-04-012009-02-23Full dose of RASS blockade versus steroids therapy in patients with IgA nephropathyFull dose of RASS blockade versus steroids therapy in patients with IgA nephropathy IgA nephropathyGroup A:Full dose of RASS blockade (ACEI and ARB blocker);Group B:prednisone ;The First Affiliated Hospital of Zhejiang UniversityNULLCompleted1870MaleGroup A:60;Group B:60;China
4EUCTR2005-003885-40-IT
(EUCTR)
18/10/200515/01/2007ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria - The primary aim of the study consists in testing the hypothesis that blockade of the RAS may decrease the risk of developing adverse effects in patients with benign IgAN.Such blockade would first achieved with unique pharmacological class then shifting to the association of the two classes as soon as ineffective blockade is documented
MedDRA version: 9.1;Level: SOC;Classification code 10038359;Term: Renal and urinary disorders
Product Name: Ramipril
INN or Proposed INN: Ramipril
Product Name: Irbesartan
INN or Proposed INN: Irbesartan
AZIENDA OSPEDALIERA PROVINCIALE DI LECCONULLNot RecruitingFemale: yes
Male: yes
Italy